Isler, BurcuOzer, BernaCinar, GuleAslan, Abdullah TarikVatansever, CanselFalconer, CaitlinDolapci, IstarSimsek, FundaTulek, NeclaDemirkaya, HamiyetMenekse, SirinAkalin, HalisBalkan, Ilker InancAydin, MehtapTigen, Elif TukenmezDemir, Safiye KoculuKapmaz, MahirKeske, SiranDogan, OzlemArabaci, CigdemYagci, SerapHazirolan, GulsenBakir, Veli OguzalpGonen, MehmetChatfield, Mark D.Forde, BrianSaltoglu, NeseAzap, AlpayAzap, OzlemAkova, MuratPaterson, David L.Can, FusunErgonul, Onder2022-11-232022-11-2320220934-9723http://hdl.handle.net/11727/8153A prospective, multicentre observational cohort study of carbapenem-resistant Klebsiella spp. (CRK) bloodstream infections was conducted in Turkey from June 2018 to June 2019. One hundred eighty-seven patients were recruited. Single OXA-48-like carbapenemases predominated (75%), followed by OXA-48-like/NDM coproducers (16%). OXA-232 constituted 31% of all OXA-48-like carbapenemases and was mainly carried on ST2096. Thirty-day mortality was 44% overall and 51% for ST2096. In the multivariate cox regression analysis, SOFA score and immunosuppression were significant predictors of 30-day mortality and ST2096 had a non-significant effect. All OXA-48-like producers remained susceptible to ceftazidime-avibactam.enginfo:eu-repo/semantics/closedAccessOXA-48OXA-232ST2096Klebsiella pneumoniaeCeftazidime-avibactamarticle4158418470007702000000012-s2.0-85126797654